Home
Clinical Trials
Expanded Access to Epcoritamab

Expanded Access to Epcoritamab

NCT ID: NCT05692050

Last Updated: 2023-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Expanded Access Program for Epcoritamab

NCT05733650

Large B-cell Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal Large B-cell Lymphoma (PMBCL) +2 more

APPROVED_FOR_MARKETING

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

NCT05660967

Diffuse Large B-Cell Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347

Diffuse Large B-Cell Lymphoma Follicular Lymphoma

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609

Follicular Lymphoma Low Grade Non-Hodgkin's Lymphoma, Adult

RECRUITING PHASE2

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

NCT06458439

Lymphoma, Non-Hodgkin Relapsed Diffuse Large B Cell Lymphoma Refractory Diffuse Large B-cell Lymphoma +2 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epcoritamab

Subcutaneous Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABBV-GMAB-3013

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- The participant must not be eligible for an epcoritamab clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C23-496

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494 ACTIVE_NOT_RECRUITING PHASE3

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759 RECRUITING

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824 ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

NCT06238648 RECRUITING PHASE2

Epcoritamab in Previously Treated WM

NCT06510491 RECRUITING PHASE2

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541 RECRUITING PHASE1/PHASE2

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

NCT06811272 RECRUITING PHASE2

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

NCT04400591 AVAILABLE

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

NCT05776160 AVAILABLE

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT06510361 RECRUITING PHASE2

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

NCT06287398 RECRUITING PHASE2

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810 ACTIVE_NOT_RECRUITING PHASE2

Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

NCT00044902 COMPLETED PHASE2

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236 RECRUITING PHASE2

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00022685 UNKNOWN PHASE3

Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

NCT06931652 NOT_YET_RECRUITING PHASE2

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357 ACTIVE_NOT_RECRUITING PHASE1

A Study of LY3039478 in Participants With Advanced Cancer

NCT01695005 COMPLETED PHASE1

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

NCT05201248 ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066 ACTIVE_NOT_RECRUITING PHASE3

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899 RECRUITING PHASE3

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06045247 RECRUITING PHASE2

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182 COMPLETED PHASE2

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

NCT01665768 COMPLETED PHASE2

Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab

NCT01131208 COMPLETED